Research Article ISSN 2639-9512

Stem Cell & Regenerative Medicine

Exploring the Potential of Stem Cell Therapy for Neurological Repair in Schizophrenia

Marley Chambers and Vincent S Gallicchio*

Department of Biological Sciences, College of Science, Clemson University, Clemson, South Carolina, USA.

***Correspondence:**
Dr. Vincent S. Gallicchio, Department of Biological Sciences, 122 Long Hall, College of Science, Clemson University, Clemson, South Carolina, USA.

Received: 08 Jan 2026; **Accepted:** 18 Feb 2026; **Published:** 02 March 2026

Citation: Marley Chambers, Vincent S Gallicchio. Exploring the Potential of Stem Cell Therapy for Neurological Repair in Schizophrenia. Stem Cells Regen Med. 2026; 10(1): 1-13.

ABSTRACT

Schizophrenia is a severe psychiatric disorder associated with emotional, behavioral, and cognitive impairment. The World Health Organization (W.H.O) ranks the illness as one of the top ten diseases contributing to the global health burden. The disease is characterized by positive symptoms, including hallucinations and delusions, alongside negative symptoms, including apathy and social withdrawal, as well as other cognitive impairments. Beyond these clinical features, there is a growing body of evidence that neurodevelopmental abnormalities, neuroinflammation, synaptic connectivity, and neurogenesis deficits are connected to schizophrenia. Traditional therapies for the mental disorder prioritize symptom control over neurological repair. Through mechanisms including immune modulation, synaptic rehabilitation, and neuronal replacement, stem cell therapy introduces the potential for an innovative investigational approach to modulate biological processes implicated in the neuropathology of schizophrenia. This study examines the current state of preclinical and clinical research on stem cell therapy in the neurological repair treatment of schizophrenia, compares the therapeutic potential of different stem cell types, and discusses barriers to clinical application.

Keywords

Schizophrenia, Stem Cells, Neurological Repair, Mesenchymal Stem Cells, Neurogenesis.

List of Abbreviations

BBB: Blood-brain barrier, BDNF: Brain-derived neurotrophic factor, Evs: Extracellular vesicles, GDNF: Glial cell-derived neurotrophic factor, GMP: Good manufacturing practice, iPSCs: Induced pluripotent stem cells, MIA: Maternal immune activation, MSCs: Mesenchymal stem cells, MAM: Methylazoxymethanol, NSCs: Neural stem cells, NSCs: Neurological stem cells, PCP: Phencyclidine, PET: Positron emission tomography, PPI: Prepulse inhibition, RCT: Randomized controlled trial, ROS: Reactive oxygen species, SV2A: Synaptic vesicle protein 2A, TGF-β: Transforming growth factor-beta, TNF-α: Tumor necrosis factor-alpha, WHO: World Health Organization.

Introduction

Schizophrenia remains one of the most debilitating and unpredictable psychiatric disorders, with a substantial proportion of patients exhibiting inadequate response to current treatments, despite decades of research committed to the disease. Schizophrenia affects approximately 1% of people worldwide, with severe impairments on the quality of life of those affected, including but not limited to social interaction and occupational functioning [1]. Traditional therapies for symptoms target dopaminergic signaling pathways through antipsychotic drugs. These drugs have shown effectiveness in managing positive symptoms, including delusions and hallucinations. However, this treatment plan offers limited alleviation for the major cognitive impairments and negative symptoms that often cause long-term disability in patients affected [2]. Even then, approximately one-third of patients suffering from schizophrenia are considered by clinical professionals to be treatment resistant to current drugs, and those that do respond to antipsychotic drugs are known to often experience significant side

effects [3]. The limitations in the current approach to treatment highlight the pressing need for innovative strategies that go beyond symptom suppression and target the repair of underlying neural abnormalities in schizophrenia.

Emerging research suggests that schizophrenia is not solely a neurotransmitter imbalance but also involves functional and structural deficiencies in the brain [1]. In patients affected by schizophrenia, neuroimaging and postmortem studies have frequently demonstrated a reduction in cortical gray matter, altered synaptic architecture, impaired neurogenesis, and chronic inflammation. These findings suggest that the current pharmacological treatments have limited capacity to modify the disorders underlying neurodevelopmental and neurodegenerative processes [4].

Considering these challenges, regenerative medicine has piqued interest as an alternative therapeutic avenue. Specifically, stem cell-based approaches offer the potential to support damaged neural cells and protect neural circuits through mechanisms such as neuroinflammatory pathway modulation, synaptic restoration, and neurogenesis stimulation. Although stem cell therapy is still in the early stages of development for psychiatric disorders, preclinical models and initial rounds of clinical trials offer promising evidence for its potential in treating the pathology of patients affected by schizophrenia [5].

This study reviews the current state of knowledge behind the neurological damage in schizophrenia and assesses how stem cell treatments have the potential to offer new strategies for neural repair. We will explore the mechanisms by which stem cells may have therapeutic effects, compile preclinical and clinical data, compare different stem cell types and each of their regenerative potential, and address the challenges and ethical dilemmas associated with implementing stem cell treatments into clinical practice. We will ultimately address the potential of stem cell therapy to treat the neural deficits in schizophrenia, and which stem cell sources hold the greatest potential in future treatment.

Neurological Damage in Schizophrenia

It has long been accepted that schizophrenia is an illness involving significant structural and functional abnormalities in the brain, stretching beyond the neurotransmitter imbalances that are typically the focus of pharmaceutical therapies. Widespread reductions in the cortical gray matter volume have been repeatedly demonstrated through neuroimaging examinations, especially in areas such as the temporal lobes, hippocampus, and prefrontal cortex [1,3]. Many of the negative symptoms and cognitive impairments that accompany schizophrenia, including impairments with working memory, executive function, and emotional control, are correlated with these structural deficiencies [5]. Additionally, disturbances to white matter integrity have been observed, indicating decreased connectivity among brain regions vital to coherent cognitive functioning.

On the molecular level, schizophrenia is linked to chronic neuroinflammation, weakened neurogenesis, and synaptic dysfunction. Postmortem studies have shown reduced dendritic spine density, which indicates interrupted synaptic connectivity and plasticity. The dysregulation of excitatory and inhibitory balance within neural networks has also been correlated with decreased levels of parvalbumin-positive GABAergic interneurons, especially in the hippocampus and prefrontal cortex [6]. Additionally, evidence of reduced adult hippocampal neurogenesis suggests an association with impaired adaptive and reparative capacity in schizophrenia. These issues are made more severe by the elevated levels of pro-inflammatory cytokines like TNF-α and IL-6 found in cerebrospinal fluid and peripheral blood, supporting the idea that persistent neuroinflammation is an important contributor to the development of the disease [1].

Region (volume)	Patients		Controls	
	Mean percentage change (%)	(95%, CI)	Mean percentage change (%)	(95%, CI)
Total GM	-0.66	(-0.74, -0.58)	-0.15	(-0.20, -0.10)
Frontal GM	-0.20	(-0.37, -0.03)	-0.16	(-0.22, -0.10)
Temporal GM	-0.11	(-0.22, 0.00)	0.28	(0.19, 0.37)
Parietal GM	-0.10	(-0.29, 0.09)	-0.48	(-0.59, -0.37)
Occipital GM	1.00	(0.76, 1.40)	0.27	(0.19, 0.35)
STG (right)	0.83	(-0.36, 2.02)	0.76	(0.39, 1.13)
STG (left)	-0.61	(-0.76, 0.54)	0.67	(0.06, 1.28)
STG (right anterior)	-0.99	(-1.31, -0.67)	0.22	(0.06, 0.38)
STG (left anterior)	-2.03	(-2.49, -1.57)	0.38	(0.12, 0.64)
STG (right posterior)	-1.62	(-1.88, -1.36)	-0.19	(-0.26, -0.12)
STG (left posterior)	-2.03	(-3.41, -2.25)	-0.38	(-0.55, -0.21)
HG (right)	-0.13	(-0.28, 0.02)	-0.40	(-0.56, -0.24)
HG (left)	-2.76	(-3.34, -2.18)	-0.39	(-0.56, -0.22)
PT (right)	-0.54	(-0.69, -0.39)	0.37	(0.31, 0.43)
PT (left)	-2.35	(-3.13, -1.57)	0.12	(0.01, 0.23)

Abbreviations: CI, confidence interval; GM, grey matter; HG, Heschl gyrus; PT, planum temporal; STG, superior temporal gyrus

Figure 1: Longitudinal changes in regional gray matter volume in individuals with schizophrenia compared to healthy control individuals.

The chart shows estimated annual percent changes in total and regional gray matter volume taken from a meta-analysis of 19 longitudinal studies that included 813 patients with schizophrenia and 718 control participants. Patients exhibited significantly larger gray matter loss over time, particularly in regions such as the frontal and temporal lobes. These findings support that schizophrenia is associated with progressive and regionally specific brain structure alterations, in addition to neurodevelopmental abnormalities alone. Adapted from Vita et. al., 2012 [4].

Collectively, these findings support the theory that schizophrenia as an illness is characterized by disrupted neural development, ongoing neurodegeneration, and insufficient endogenous repair. Current pharmacological therapies, while effective in some individuals for reducing positive symptoms, do not address the underlying pathophysiological processes. As a result, regenerative techniques aimed at synapse restoration, neurogenesis augmentation, and immunomodulation, such as stem cell therapies, represent a promising investigational approach for addressing key neurological contributors to schizophrenia [7].



Figure 2: Image illustrating the interconnected roles of neuroinflammation, oxidative stress, and mitochondrial dysfunction in the pathophysiology of schizophrenia.

Persistent inflammatory signaling promotes oxidative harm and mitochondrial impairment, which contribute to synaptic dysfunction and reduced neurogenesis. Modulation of these pathways represents a potential target for regenerative therapeutic strategies [1].



Figure 3: Whole brain maps of synaptic vesicle protein 2A (SV2A) binding in individuals with schizophrenia compared to healthy controls, measured using [^{11}C]UCB-J positron emission tomography (PET).

Reduced SV2A signal in schizophrenia, particularly in the frontal and temporal regions, indicates the widespread loss of synaptic density. These findings provide in vivo evidence of synaptic pathology as a prominent feature in schizophrenia and highlight synaptic integrity as a critical therapeutic target for regenerative-based interventions [4].

Mechanisms of Stem Cell Therapy

Therapies based on stem cells present several potential methods to treat the underlying neurological damage observed in schizophrenia. At the cellular level, stem cells may influence neural circuits through mechanisms distinct from conventional pharmacological approaches, including paracrine signaling and modulation of plasticity [2]. The following mechanisms display hypothesized biological actions of stem cells observed in schizophrenia models.

Promotion of Neurogenesis

Certain stem cell types, specifically neural stem cells (NSCs) and induced pluripotent stem cells (iPSCs), have the potential to differentiate into neurons and glial cells. This ability is significant for the potential treatment of schizophrenia as the extreme cognitive deficiencies observed in patients are largely attributed to impaired adult neurogenesis, particularly in the hippocampus [1]. In theory, transplanted stem cells have the potential to differentiate into neural lineages or stimulate endogenous neural progenitor cells to enhance neuronal regeneration.



Figure 4: Overview of the proposed mechanisms underlying stem cell-based therapeutic approaches for schizophrenia.

Stem cells derived from multiple sources can be administered via grafting or infusion, exerting their therapeutic effects through paracrine signaling, including the release of neurotrophic, angiogenic, anti-inflammatory, and anti-apoptotic factors. These processes support neuroplasticity, neurogenesis, and functional circuit repair. Adapted from [2].

Enhancement of Synaptic Plasticity

Synaptic connectivity is frequently disrupted in patients experiencing schizophrenia, leading to cognitive and social functioning deficiencies. Neurotrophic factors, such as glial cell-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) [8], are secreted by stem cells to promote synaptic growth, development, and plasticity. Over time, these elements improve circuit performance by stabilizing already existing synapses and stimulating the formation of new synaptic connections to support synaptic stability and adaptive circuit-level changes over time [5].

Modulation of Neuroinflammation

One of the major symptoms observed in schizophrenia is chronic neural inflammation, linked with persistent brain damage. Immunomodulatory responses are particularly significant in mesenchymal stem cells (MSCs). They secrete anti-inflammatory cytokines such as IL-10 and transforming growth factor-beta (TGF-β) while reducing pro-inflammatory mediators like tumor necrosis factor-alpha. (TNF-α). Through the alteration of the immunological environment from a pro-inflammatory to an anti-inflammatory state, stem cell treatment may reduce or slow further degeneration of susceptible neurons [5].

Protection Against Oxidative Stress

The etiology of schizophrenia has been linked to oxidative stress, caused by an imbalance between antioxidants and free radicals. To maintain the integrity and functionality of neurons, stem cells can

strengthen antioxidant defenses and release protective molecules that have the capacity to neutralize reactive oxygen species (ROS) [9], and in doing so protect neuronal integrity and function.

Restoration of Myelination

Patients affected by schizophrenia show white matter abnormalities, including impaired myelination [4]. NSCs and oligodendrocyte precursor cells derived from iPSCs represent certain neural stem cells that can differentiate into oligodendrocytes and aid in the remyelination of damaged axons [10]. This procedure has the potential to improve signal transmission efficiency across neural circuits and restore connectivity.

Delivery of Therapeutic Factors via Extracellular Vesicles

According to recent research, exosomes or extracellular vesicles (EVs) derived from stem cells may be able to replicate many of the advantageous effects of living stem cells. Without the dangers and risks associated with stem cell transplantation [3]. These vesicles contain bioactive molecules such as proteins, lipids, and microRNAs that, when transmitted into host cells, may alter molecular pathways that have the potential to alter inflammation, stimulate neurogenesis, and enhance synaptic plasticity [9].

In summary, stem cell therapies employ a variety of strategies rather than a single method of action, encompassing cell replacement, support of damaged neurons, the decrease of harmful inflammation, and stimulation of the brain's regenerative mechanisms [2]. The combination of paracrine support and circuit reconstruction may be essential in the context of schizophrenia, where widespread and functionally coupled brain regions are damaged. Instead of merely reducing symptoms, stem cell therapies have the potential to address the underlying biological deficiencies of schizophrenia by simultaneously supplying new neural components and protective factors.

Preclinical Evidence

Preclinical research in cell culture and animal models has demonstrated the feasibility of stem cell-based therapies in reducing the neuropathology and behaviors associated with schizophrenia [7]. Rodent models of schizophrenia, including pharmacological models (e.g., phencyclidine or amphetamine sensitization), developmental disruption models (e.g., methylazoxymethanol acetate exposure), and immune activation models, have been useful in the testing of stem cell therapies [6]. Below is a summary of the main conclusions drawn from these studies:

MSC Transplantation Enhances Neurogenesis and Behavior

Gobshits et. al., [7] introduced transplanted MSCs derived from bone marrow into the brains of mice exposed to neonatal ketamine, a neurodevelopmental model of schizophrenia. Increased levels of doublecortin-positive new neurons in the dentate gyrus suggest that the MSCs, which were administered intracerebroventricularly, significantly increased adult hippocampal neurogenesis and survived for months. Remarkably, the impact of a single MSC injection lasted for months; treated mice exhibited improvements in social novelty preference and prepulse inhibition (PPI), a measure of sensorimotor gating, in comparison to control mice. Crucially, these advantages persisted for long after the cells were administered, in contrast to the short-term effects shown in antipsychotic administration in drugs like clozapine. Additionally, the study discovered that later behavioral improvements (at 3 months) corresponded with higher DLL1 (notch ligand) expression, and early behavioral improvements (at 2 weeks) correlated with increased hippocampus FGF2 expression. These findings suggest that MSCs created a long-lasting pro-neurogenic environment. This offers strong preclinical support that MSC therapy can enhance neuroplasticity and support neural stem cell niches through mechanisms distinct from conventional pharmacological treatments, improving deficiencies like those observed in schizophrenia [7].

Intranasal MSC Exosomes Rescue Circuitry

Tsivion-Visbord et al., [3] demonstrated that MSC secretions are therapeutic in and of themselves, building on previous research that suggested that cerebral MSC transplants could reduce behaviors resembling schizophrenia. Extracellular vesicles (EVs, exosomes) produced from MSCs were administered intranasally (a non-invasive delivery method to the brain) in a mouse model induced by phencyclidine (PCP). Main symptoms of schizophrenia like behavior were significantly improved by MSC-EVs. Mice treated with the MSC-EVs regained their normal social interactions and PPI startle responses, which the PCP had disrupted. The number of parvalbumin-positive interneurons, which typically decreases following PCP exposure, was kept at nearly normal levels in EV-treated mice, indicating that the EV therapy also retained GABAergic interneurons in the prefrontal cortex. The excess glutamate in the cerebrospinal fluid linked to PCP toxicity was also absent in the EV-treated mice, suggesting that glutamatergic neurotransmission had returned to normal. According to these findings, components of MSC-derived vesicles may shield interneurons and avoid excitotoxic imbalances, restoring cortical circuit function. The study confirmed that fluorescently labeled EVs administered intranasally moved primarily to the prefrontal cortex, the place most affected by PCP injury. This makes the use of intranasal distribution significant because it uses a pathway to bypass the blood-brain barrier. This supports the potential that exosome-based cell-free stem cell therapy can aid in the normalization of circuit dysfunction in models of schizophrenia [3].

ESC-Derived Interneuron Transplants Normalize Activity

Donegan et al., [6] transplanted interneurons produced from embryonic stem cells into the hippocampus of a schizophrenia rat model organism, offering an impressive demonstration of cell replacement therapy. Using a methylazoxymethanol (MAM) rat model that exhibits hippocampal hyperactivity and dopamine dysregulation, they generated an enriched population of GABAergic interneuron precursors (parvalbumin or somatostatin subtype) from mouse ESCs and grafted them into the ventral hippocampus. Electrophysiology confirmed that the transplanted interneurons established new inhibitory synapses onto hyperactive pyramidal neurons, demonstrating their functional integration

into the host circuitry. The presence of the new interneurons repaired previously aberrant neuronal activity, including deviated firing of dopamine neurons in the ventral tegmental region and hippocampal hyperactivity. As a result, the rats' behaviors improved significantly. The transplant recipients showed improvement in social interaction and cognitive flexibility (e.g., decreased perseveration), modeling a reduction of cognitive and negative symptoms. Notably, the model's major behavioral abnormalities were substantially alleviated by transplants enriched in parvalbumin-expressing cells, which exhibited the greatest therapeutic effects. This study provides a compelling example of how neural networks and behavior in schizophrenia can be modulated by substituting a specific neuronal subtype. It also emphasizes the potential of pluripotent stem cells, like ESCs or iPSCs, can provide almost any neural cell needed for repair [6].

Systemic MSC Infusion via Immunomodulation

Stem cell therapy has also been explored in models of schizophrenia that involve inflammation and peripheral immune activation. You et al., [11] investigated an amphetamine-sensitized mouse model of schizophrenia, which demonstrated not only behavioral deficits but also an immune signature, elevated inflammatory cytokines like those found in some human patients. When compared to the untreated psychosis-model mice, the treated mice exhibited enhanced social interaction, stabilized PPI, latent inhibition, and decreased hyperactivity and anxiety-like behavior after being given a single intravenous dose of human umbilical cord-derived MSCs. Notably, this mechanism was linked to immune-mediated modulation; the MSC infusion suppressed peripheral TNF-α and increased regulatory T-cells and IL-10, which in turn reduced brain microglial activation. The researchers demonstrated *in vitro* that MSC-derived conditioned medium may directly reduce microglial inflammatory responses. These findings support the theory that paracrine signals from MSCs acting in the periphery can transmit benefits to the brain, in this case, by creating an anti-inflammatory environment that indirectly protects the brain, since systemically delivered MSCs likely do not cross the intact blood-brain barrier in large numbers. The long-term results were worthwhile; a single infusion resulted in a prolonged reduction in neuroinflammation and a restoration of normal behavior in the mice, although the MSCs would not stay in the body long. This holds potential promise for managing an inflammatory subtype of schizophrenia in humans with a comparatively low-risk therapy method, such as recurrent intravenous MSC infusions [11].

Neural Stem Cells and Microglial Crosstalk

Further preclinical data support the positive function of stem cells in modulating brain development in pathological conditions. In a maternal immune activation (MIA) model, where prenatal exposure to inflammatory signals results in offspring with schizophrenia related abnormalities, treatment with human umbilical cord blood MSCs in the early postnatal period was shown to prevent anxiety-like behavior and cognitive deficits in adult offspring [12]. In this model, MSC therapy protected the neonate's neural progenitor cells from the detrimental effects of inflammation by altering the activation states of microglia in the developing brain, shifting them toward an anti-inflammatory phenotype linked to arginase-1 expression. Although the specifics of this study are outside the scope of this review, it is consistent with an increasing amount of evidence that shows improved neurodevelopmental outcomes in schizophrenia models are linked to improved neuroimmune modulation by stem cells.

All things considered, preclinical research offers compelling evidence that stem cell-based therapies can modulate several pathological aspects of schizophrenia. Behavioral phenotypes, including those that resemble difficult-to-treat negative and cognitive symptoms, have improved. Underlying neuropathology, such as interneuron impairments, abnormal neurotransmission, excessive inflammation, and deficient neurogenesis, has been treated. These varied examinations, which range from MSC secretome administration to neuron replacement, highlight the possibility that there are multiple approaches to using stem cells for treatment. Future challenges include converting these achievements into clinically effective therapies and determining the most suitable kind of stem cell intervention for the complex pathology of schizophrenia.

Stem Cell-Based Approaches to Neurological Repair

The potential of various stem cell types and products derived from stem cells to repair neurological damage in schizophrenia is being investigated. Each stem cell type has specific advantages and limitations. Mesenchymal stem cells (MSCs), neural stem cells (NSCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs) are the primary stem cell-based therapies. We will address each one independently:

Embryonic Stem Cells (ESCs)

The inner cell mass of blastocyst stage embryos gives rise to pluripotent cells known as embryonic stem cells. They provide an almost limitless supply of neurons, glia, or other cells for transplantation because they can differentiate into any type of cell found in the body. In theory, ESCs may be programmed to generate the particular neuronal cell populations, such as oligodendrocytes, dopaminergic neurons, or GABAergic interneurons, that are deficient or malfunctioning in schizophrenic patients. ESC-derived neural progenitors, like the ESC-derived interneurons in the hippocampus transplant study, have already been employed in preclinical research to treat models of schizophrenia. If the proper cells are placed in the right location, ESC-derived neural cells can integrate both physically and functionally into adult brain circuitry, indicating that cell replacement treatment may be feasible under specific conditions [6]. However, ESC-based treatment has several limitations. Immune rejection is a significant problem because most recipients will not have immunologically matched ESC lines because they are allogenic or derived from a donor embryo. Transplanting ESC may result in host immune responses unless immunosuppression is utilized, complicating long-term therapy. Another issue is accessibility and ethics. Using human embryos presents moral dilemmas and is governed by laws in numerous countries [13]. Furthermore, if any undifferentiated cells are transplanted, ESCs run the risk of developing into teratomas,

which are benign tumors with a mixture of cell types [14]. To guarantee that there are no pluripotent cells left in a transplant, differentiated progeny must undergo rigorous purification.

ESCs are nonetheless a useful research tool despite these limitations. They offer a pluripotent cell that is regarded as the baseline for developing differentiation methods. Researchers have utilized ESCs to investigate developmental processes linked to schizophrenia and to establish *in vitro* models of the disease (e.g., co-culturing ESC-derived neural cells with patient cells to evaluate interactions) [2]. In the future, ESC-derived products may primarily be used indirectly in the treatment of schizophrenia. For example, ESC-derived cells could be used to make standardized batches of growth factors or exosomes as a commercially available therapeutic product, avoiding the need to implant the cells themselves. Any ESC-based transplant therapy in patients will most likely involve the creation of cell banks with various immune profiles or the gene editing of ESCs to minimize immunogenicity.

In conclusion, ESCs are versatile and can theoretically produce the entire range of neural cells required for repair. However, overcoming ethical and immunological barriers will be necessary before they can be used in the practical treatment of schizophrenia. Their ability to supply specific neuron types, such as inhibitory interneurons that are absent from particular circuits or serve as a platform for the discovery of molecules that promote neural repair may be their most promising contribution.

Induced Pluripotent Stem Cells (iPSCs)

Adult somatic cells, such as skin fibroblasts or blood cells, that have been reprogrammed into a pluripotent state by inserting essential transcription factors are known as induced pluripotent stem cells [15]. iPSCs are functionally comparable to ESCs in terms of differentiation capacity, but they can be generated from individual patients. Because of their autologous origin, iPSC-derived cells transplanted back into the same patient would be immunologically compatible, preventing rejection and avoiding the need for immunosuppressants. The development of iPSC technology made it possible to create disease models and regenerative treatments tailored to individual patients.

Schizophrenia research has already been significantly impacted by iPSC technology. From iPSC lines derived from schizophrenia patients, researchers have differentiated them into neurons, neural progenitors, and neural organoids (3D mini-brains). These patient-derived neural cells frequently exhibit cellular characteristics indicative of the disorder's pathophysiology, such as altered synaptic protein expression, abnormal neuronal interactions, and excitatory/inhibitory neuron ratio imbalances [2]. In line with developmental theories of schizophrenia, for example, one study found that neural progenitors grown from iPSCs from patients had dysregulated Wnt signaling and generated an abnormal mixture of neurons. These findings indicate that iPSC models can replicate specific cellular and developmental features associated with elements of schizophrenia, offering insight into the causes and permitting the screening of new medicines in a patient-specific context [16].

When it comes to therapeutic applications, iPSCs show immense potential, but they also present obstacles. On the plus side, autologous iPSC-derived brain cells may theoretically be used to replace or support dysfunctional neural circuits in a patient without immunological problems. To increase inhibitory signaling, for instance, it might be possible to create iPSCs from a skin sample taken from a patient with chronic schizophrenia, differentiate them into GABAergic interneuron precursors, and transplant those into the patient's hippocampus or cortex regions. This approach is comparable to animal research conducted with ESC-derived cells, but using the patient's cells may be immunologically safer.



Figure 5: Overview of schizophrenia associated cellular and molecular abnormalities identified using induced pluripotent stem cell models (iPSC).

Patient-derived iPSCs differentiated into neural progenitors and neurons replicate key features of pathophysiology, including the disruption of neural development, morphological complications, mitochondrial and ion channel dysfunctions, excitatory and inhibitory imbalance, and the dysregulation of dopaminergic signaling. These models provide a patient-specific guide for studying the mechanisms of the disease and therapeutic development. Adapted from [16].

Patient iPSCs could be modified using CRISPR/Cas9 or other genome editing technologies to add protective genes or fix known harmful mutations, producing a "repaired" autologous cell line for transplantation [17]. Another approach is to collect iPSCs from healthy donors or relatives who have suitable tissue types (allogeneic iPSCs), which are then differentiated into therapeutic products. This compromises some personalization but may ensure the cells are from a genome not affected by genes linked to schizophrenia. The time and expense of producing patient-specific iPSCs and neurons is the final practical problem of iPSC therapy. This process can take months and is labor-intensive, making it impractical for a clinical therapeutic pipeline. Researchers are investigating ways to improve this, such as banks of pre-made

iPSC lines reflecting common immune types or even direct conversions of fibroblasts to neurons (skipping the entire iPSC stage) to produce transplantable cells rapidly.

In conclusion, iPSCs combine the versatility of ESCs with the personalization of autologous therapy, making them a promising candidate for creating schizophrenia remedies requiring neuron replacement or patient-specific disease models. Their significance in schizophrenia treatment may begin with tailored in vitro testing platforms for drug screening or brain organoid models to investigate disease mechanisms. Long term, improving neurological systems in treatment-refractory schizophrenia may be possible with iPSC-derived neural cell transplants, or perhaps improved by gene editing, if complications with pathological memory and manufacturing are addressed.

Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells are multipotent stromal cells that are commonly derived from adult tissues such as bone marrow, adipose tissue, or birth-associated tissues such as the umbilical cord. MSCs may differentiate into mesodermal lineages (bone, cartilage, fat) and, under some conditions, into other cell types, but their primary therapeutic usefulness is in the secretion of molecules with bioactive and immunomodulatory features rather than transdifferentiation directly [18]. MSCs have repeatedly shown the ability to home to injury sites and release molecules that support neuroprotection, reduce inflammation, and promote regeneration in neurological disorders [18,19]. Due to their superior safety profile and convenience of administration, MSCs are now the most widely researched stem cell type for schizophrenia in preclinical models. MSCs have indirect therapeutic effects that can be highly potent, unlike neural stem cells, which naturally integrate into neural circuits as new neurons. MSCs have the following main benefits:

1) Ease of Isolation and Expansion: MSCs can be easily isolated from bone marrow aspirates or fat via minimally invasive procedures, and they can be cultured to high quantities required for therapy [18].
2) Allogeneic Use: MSCs are immunoprivileged to some extent and have been employed allogeneically (donor to host) in several trials without rejection concerns because they exhibit low amounts of MHC-II and can actively inhibit immune responses. This implies that a universal donor MSC line may be able to treat many patients [18,19].
3) Established Safety: Trials utilizing MSCs for various ailments (such as multiple sclerosis, stroke, and Crohn's disease) have demonstrated that administering MSCs intravenously or intracerebrally is generally safe and well-tolerated, with few serious side effects other than sporadic feverish reactions [18]. This safety record paves the way for psychiatric use.

Preclinical research suggests MSCs can improve schizophrenia-like symptoms through various pathways, including anti-inflammatory activity (raising IL-10, TGF-β, and lowering microglial activation) [11,18], neurotrophic support (elevating BDNF, NGF, etc.), and encouraging endogenous neurogenesis. One notable component is that even extracellular vesicles from MSCs retain similar properties, implying that cell-free MSC-derived therapies may be feasible while avoiding concerns such as embolism or unintentional differentiation [3,9]. By altering peripheral immunity and communicating with the brain through exosomal signals, MSCs can be administered intravenously or intranasally while continuing to provide benefits to the central nervous system [9,11]. Since a portion of people with schizophrenia have peripheral inflammatory signs, this non-direct route is highly significant; MSC infusions may be capable of alleviating an overactive immune system that is causing brain dysfunction [11].

MSCs represent one of the most clinically advanced stem cell approaches currently under investigation for schizophrenia from a mechanistic approach. They don't have the same ethical issues as ESCs, and unlike iPSCs, their use doesn't include tumorigenic cells or irreversible genetic changes. In individuals with schizophrenia, particularly those who exhibit signs of inflammation or neuroprogression, MSC therapy may entail a series of intravenous infusions or even intranasal applications of MSC-derived exosomes if efficacy is verified. The intention would be to gradually enhance cognitive performance or negative symptoms by mending brain circuits over time, rather than "curing" schizophrenia overnight. A pilot open-label study in 15 patients with refractory schizophrenia used repeated IV infusions of allogeneic human umbilical cord blood cells over 8 weeks; at 3 months post-treatment, the patients showed increased frontal cortical activity on fMRI and some improvements in working memory, which may reflect altered neural engagement or neuroplasticity [20]. In humans with schizophrenia, this offers an initial suggestion that MSC-based therapies may be safe and biologically active; however, controlled trials are required.

It is important to remain aware that MSC treatment has its limitations. MSCs do not normally develop into neurons, therefore, if a patient's schizophrenia is caused by the loss of a certain type of neuron, MSCs alone may not be able to replace those cells [18]. The field has also shown that not all MSCs are produced equally, the potency of MSCs might vary depending on the culture conditions, donor age, and tissue source (bone marrow, adipose, or cord) [18]. Also, the duration of effect is considered: Unless they cause self-sustaining modifications in the brain, as some rodent studies have suggested, MSCs frequently do not last long after injection, weeks at most if not immune-protected, so recurrent dosage may be necessary to maintain effects.

To summarize, MSCs make up a practical and currently accessible method to stem cell therapy for schizophrenia. Instead of rebuilding circuits one cell at a time, they are excellent at creating a protected, pro-regenerative environment [3,18]. Given their strong rationale and safety record, future trials utilizing MSCs or MSC-derived exosomes to address the neurological components of schizophrenia are likely in development.

Neural Stem Cells (NSCs)

In the developing or adult nervous system, neural stem cells are

progenitor cells devoted to producing neural lineages, which include neurons, astrocytes, and oligodendrocytes. In adults, NSCs persist in areas such as the subventricular zone of the lateral ventricles and the subgranular zone of the hippocampus dentate gyrus, resulting in limited neurogenesis throughout life. To enhance brain restoration, NSC-based therapy either stimulates the patient's own neural stem/progenitor cells or transplants exogenous neural stem/progenitor cells.

Since NSC techniques directly target the brain's capacity for regeneration, they are conceptually promising for treating schizophrenia. The pathophysiology of schizophrenia has been linked to impaired neurogenesis in the hippocampus [21]. Increasing NSCs could assist with cognitive deficits by enhancing brain circuits by generating new neurons and glia. Transplanted NSCs may potentially move to areas of damage or dysfunction in the brain, differentiate correctly, and provide trophic support along their path. These theories are supported by certain preclinical research, which demonstrated that grafting adult or fetal neural stem cells into mice might raise local BDNF levels and buffer them from the social behavior impairments brought on by PCP [22]. The ability of NSCs to naturally integrate into the brain and replace neural cells, in contrast to MSCs, may be necessary for repairing specific circuit damage.

In related neurological illnesses, NSCs have been used in exploratory clinical research [10]. A few trials have suggested that NSCs may be used in psychiatric disorders [10]. Lessons from the longer history of NSC transplants in conditions like Parkinson's disease and spinal cord injury can be applied here. For instance, human fetal-derived NSCs have been tested in Huntington's disease and have been shown to survive and produce neurons in patients' brains, although exhibiting only modest functional improvement [10]. The purpose of NSC infusion in schizophrenia is likely to restore interneurons or glial support cells in the hippocampus or prefrontal cortex. The capability of NSCs to respond to cues from the host environment may be beneficial if a region is experiencing neuroinflammatory stress or myelin deficiencies like oligodendrocyte loss observed in schizophrenia. NSCs may differentiate preferentially into the required cell type, such as astrocytes or oligodendrocytes, to help alleviate that problem.

Source and control are the main challenges for NSC therapy. Primary neural stem cell collection from fetal tissue is a problematic and confined ethical practice. Thus, NSCs produced from immortalized NSC lines or pluripotent stem cells (ESC or iPSC-derived NSCs) are now used in the majority of NSC therapy studies. If the cells are not completely regulated, the latter may give rise to worries regarding tumorigenicity. Since NSCs have been transplanted in a significantly smaller number of human instances than MSCs, which have been used in hundreds of patients, there is less information available regarding their long-term safety profile. If transplanted NSCs are not appropriately characterized before transplantation, there is a slight likelihood that they will develop into tumors or differentiate in detrimental ways.

Getting NSCs to accomplish what we want in the complicated environment of a schizophrenic brain is another difficulty. The mere introduction of NSCs does not ensure their beneficial incorporation; they could relocate improperly or remain dormant. Creating "enhanced" NSCs by manipulating them to express specific guidance molecules or secrete factors is one way to get around this. In neurodegenerative models, for instance, NSCs overexpressing BDNF have been used to increase neurotrophic support beyond what standard NSCs would provide.

The concept of utilizing NSCs to regenerate neurons is still appealing despite these obstacles. The broad pathophysiology of schizophrenia may not be ideal for a focused NSC graft, unlike Parkinson's disease, which targets dopaminergic neurons in the substantia nigra. By stimulating the patient's NSCs in the hippocampus to increase neurogenesis, or by introducing NSCs into cerebral ventricles where they can spread and integrate in multiple areas, NSC therapy for schizophrenia could instead aim to improve plasticity more broadly [21,22]. To accomplish a similar objective as cell grafting, some recent research is looking at medications that activate endogenous NSCs, such as experimental medications or several antidepressants, as a more indirect but readily deliverable method.

In conclusion, neural stem cell therapies aim to support and modify the compromised brain architecture in schizophrenia. Although research is still in its early phases, NSC stimulation or transplantation may aid in hippocampus regeneration, enhance cortical connectivity, and offer long-term relief of behavioral and cognitive symptoms [2,10]. The success of these strategies will rely on how precisely the right cells are delivered to the right location and how well they integrate and differentiate.

Clinical Applications and Ongoing Trials

Therapeutic use of stem cells for schizophrenia is still in its early stages of clinical development. In comparison to neurological conditions such as Parkinson’s or strokes, which have had ongoing stem cell trials, schizophrenia has only seen a small number of preliminary human investigations [2,21]. However, a number of these early clinical initiatives are actively moving forward and offer valuable insights regarding safety and viability. This section provides an overview of human progress and projected directions for research.

Safety and Feasibility Studies

Demonstrating safety is the primary objective when bringing stem cell therapy to the clinic. Ternovoy et al., [20] conducted an innovative pilot study in 2020 to assess the safety of administering multiple infusions of cells made from umbilical cord blood to individuals suffering from schizophrenia [22]. In that study, 15 patients with chronic schizophrenia (ICD-10 F20.6) were monitored for several months after being treated with four intravenous infusions of cord blood mononuclear cells, including hematopoietic stem cells and MSCs, staggered two weeks apart. Repeated stem cell infusions were well tolerated, as indicated by the lack of serious side effects reported. The researchers utilized

fMRI to search for changes in brain function, although this was an open-label trial without a control group. Remarkably, during a verbal working memory task, three months after the last infusion, patients displayed enhanced activation in frontal and parietal cortical areas. It was speculated that this rise in cortical activity may reflect altered neural engagement or plasticity, although causal interpretation is limited by the open-label design. Clinically, some cognitive improvement was observed, but no definitive conclusions about performance can be formed without controlled data. This study suggested possible cognitive improvements and is preliminary support of systemically administering stem cells is safe and possible in schizophrenia patients [22].



Figure 6: Diagram illustrating how adult neurogenesis may act as a buffering mechanism against stress-related pathology.

Genetic vulnerability, inflammation, and chronic stress negatively regulate neurogenesis, while pharmacological treatments, behavioral interventions, exercise, and environmental enrichments may enhance neurogenic processes. Increased adult neurogenesis is proposed to promote stress resilience, a mechanism relevant to emerging stem cell-based therapeutic strategies in schizophrenia. Adapted from [22].

Ongoing Trials with MSCs

Current clinical efforts have focused on MSC-based therapies due to their safety and promising preclinical profile [2,10]. To reduce negative symptoms and cognitive deficits, allogeneic MSC infusions are being investigated in a small number of registered trials, based on clinical trial databases and literature, for schizophrenia or schizoaffective disorder. For example, research facilities are examining whether individuals who respond only partially to antipsychotics can benefit from additional MSC therapy. To see whether the combination produces better improvements in functional parameters. One institution suggested pairing MSC infusions with continuous antipsychotic medication [2]. Other trials are combining stem cell therapy alongside conventional treatments. While the trials' results have not yet been released, their completion in the years to come will provide insight into whether the immunomodulatory approach will result in quantifiable clinical advancements.

The use of exosomes produced from mesenchymal stem cells as a treatment option is another possibility that is being studied [9]. Exosomes may be capable of more easily passing across the blood–brain barrier and potentially prevent some of the hazards associated with cell transplantation. At least one early-stage study is currently being conducted to evaluate the safety and neuroinflammation biomarkers, such as cytokine levels and imaging of microglial activation, of intranasal delivery of MSC-derived exosomes in patients with neuroinflammatory features of schizophrenia. Preclinical findings like Tsivion-Visbord's study, which indicate that intranasal EV administration can target the brain and enhance outcomes like schizophrenia, provide the foundation. These human studies will look at dose, appropriate frequency, and whether exosomes could lead to cognitive or functional changes in patients in the same way that they improve mouse behaviors [3].

Neural Transplantation Trials

Direct neural cell transplantation has not been clinically evaluated for schizophrenia; however, there have been recent human trials in Parkinson's disease that provide important translational context for the feasibility of these types of approaches for application in neurological disorders. A phase 1/2a, open-label clinical trial demonstrated that bilateral intracerebral transplantation of high-purity human embryonic stem cell-derived dopaminergic progenitors into the putamen was possible and well tolerated, as there was no evidence of tumor formation, abnormal overgrowth, or any graft-related adverse events over a 12-month period [23]. Some of the exploratory outcomes showed dose-dependent motor improvement and increased dopamine transporter binding on PET imaging, supporting graft survival and the successful integration into the host's neural circuits [23]. While these findings are in Parkinson's disease, these findings establish that stem cell-derived neural progenitors can be safely manufactured, surgically delivered, and functionally integrated in the adult human brain. This study and its findings provide a foundational framework for considering future applications in psychiatric disorders such as schizophrenia.

Other Relevant Clinical Developments

Stem cell therapies are also being investigated for comparable neurodevelopmental or psychiatric disorders, which may help guide treatment for schizophrenia. For example, cord blood or MSC infusions have been utilized in several autism spectrum disorder trials to enhance social functioning by lowering neuroinflammation. Stem cell therapies in the central nervous system are becoming more widely accepted because of several of these autism trials' slight improvements and safety [2,10]. Similarly, MSC infusions have been studied in early trials for treatment-resistant depression; one was intended to employ allogeneic MSCs in combination with antidepressants.

Regulatory Path and Future Trials

No stem cell treatment for schizophrenia has obtained regulatory approval or progressed to Phase III trials as of 2025. Phase I/II trials are currently taking place to evaluate safety, dosage, and initial efficacy [2]. More structured trials are anticipated soon. For instance, a randomized controlled trial (RCT) comparing MSC infusions to a placebo in patients who continue to experience

negative symptoms may be conducted shortly to measure changes in brain imaging and functional outcomes over six to twelve months. Trials utilizing combined techniques, such as stem cells plus pro-neuroplastic pharmaceuticals, are another expected advance. Combining stem cell therapy with substances like ketamine or cognitive enhancers is a unique concept that has been proposed in recent research [2]. This creates a highly dynamic environment that maximizes the effectiveness of the potential treatment plans.

In conclusion, stem cell treatment for schizophrenia is being implemented in clinical settings gradually and cautiously. Initial findings suggest that the treatments are safe and feasible, and they also point to potential cognitive benefits. In addition to symptom reduction, ongoing and new trials will assess if these interventions can result in clinically significant enhancements in patients over the following ten years, such as improved autonomy, professional competency, or social functioning. As we move forward with the translation from bench to bedside, it will be essential that we closely evaluate both efficacy and any long-term negative consequences, such as immune sensitization or ectopic tissue growth.

Challenges and Ethical Considerations

Before stem cell therapy can become a widely used treatment for schizophrenia, several ethical, practical, and scientific challenges must be addressed. The main concerns are listed below:

Complex Pathology and Treatment Targeting

Targeted treatment for schizophrenia patients is largely complicated by the vast and varying nature of the disease. Unlike a focal neurological lesion, schizophrenia affects numerous altered neurotransmitter systems and interconnected regions like the prefrontal cortex, hippocampus, thalamus, and more. Altered neurotransmitter systems. This presents the question of where stem cells or their derived products should be administered to achieve the maximum potential effects. Abnormalities in one area (like the hippocampus) may not be directly corrected by transplanting cells to another. While certain methods, such as intravenous MSCs, reach the brain indirectly, they cast a broad net. There is significant variation across individuals, with some having more inflammatory characteristics and others having more neurodevelopmental abnormalities, meaning that a single therapy may not be effective for everyone. This highlights the necessity for tailored treatment, such as determining whether individuals may benefit from neuronal replacement vs those who are more likely to react to immunomodulatory stem cell therapy. Genetic, neuroimaging, or cytokine profiles are examples of indicators that may be used to categorize patients for the best kind of stem cell treatments [2].

Delivery and Survival of Stem Cells

The blood-brain barrier (BBB) is the primary challenge to transporting cells to the CNS. Only a small percentage of systemically injected stem cells may reach the brain, while the majority become stuck in peripheral organs like the lungs or spleen. Even intranasal administration, which circumvents the blood-brain barrier by taking advantage of neural pathways, may not be effective for large cells. Although it is an option, direct intracerebral transplantation (by neurosurgery) is invasive and associated with heavy risks such as infection or hemorrhage [2]. It can be difficult to guarantee cells' survival and proper integration in the possibly incompatible brain environment, even in cases where delivery is effective. The schizophrenic brain may have high levels of oxidative stress that restrict graft survival or microglial activation that could damage transplanted cells.

Allogeneic cell survival may be aided by immunosuppressive medications, but at the expense of adverse effects. Due to their immunosuppressive properties, host reactions to grafts are less of an issue with MSCs, however, unless they are autologous, they should be considered when using neural progenitors. The problem of relocation also exists. Transplanted cells may disperse randomly or move away from their intended location. Side effects could result from unregulated migration. For example, obstructions or seizures could occur if stem cells meant for the cortex move to the ventricular system [13].

Functional Integration and Regulation

The ability of ESC/iPSC-derived neurons, or NSCs, to integrate effectively into an adult patient's complex neural networks is a major unknown for treatments that seek to replace or add neurons. Transplanted neural cells can typically integrate in a developing brain, but in an adult with schizophrenia, when pre-existing circuits are long-established and occasionally abnormal, the integration may not be as effective. Grafted neurons run the danger of incorrectly wiring, which could result in adverse effects, including seizures, erratic behavior, or even the emergence of new psychotic symptoms if they disrupt the balance of brain activity. It may be necessary for transplanted cells to not only survive but also form extremely particular connections to achieve the precise functional effects we aim for, such as improved cognition. To overcome this, scientists are looking into ways to pre-differentiate cells into particular subtypes and possibly even use bioengineering techniques to direct the growth of their axons. However, it is an exceptionally high standard to make sure that a cell therapy benefits and does not harm such a delicate organ system [14].

Durability and Monitoring

It is currently unknown how long the benefits of successful stem cell treatment would last. With this unknown, multiple administrations will probably be necessary. Repeated treatments are likely to raise concerns about accumulated hazards; repeated treatments also present logistical and economic concerns. However, some stem cell effects (one-time transplants) may be permanent or long-lasting. The problem of monitoring and reversibility is introduced by permanent alterations. A live graft can last a lifetime, in contrast to a medication that leaves the body. We would need to act, like excision of the graft, if something went wrong, such as if an iPSC-derived graft began to overgrow or produce pain. For this reason, some experimental research employs safety switches, often known as suicide genes, in transplanted cells [14]. To track the status of their grafts, patients would probably need lifelong follow-up with recurring brain imaging. Patients must get counseling regarding

these unknowns, and the medical community will require protocols for handling unanticipated effects.

Manufacturing and Quality Control

In terms of practice, creating stem cell treatments that satisfy clinical-grade requirements is challenging. For cells to be safe, free of impurities and mutations, and repeatable, they must be grown and differentiated following Good Manufacturing Practice (GMP) [2]. Each patient's cells would be a distinct product for autologous iPSC treatments, which is very expensive and time-consuming. Artificial "off-the-shelf" goods, such as neural progenitor lines or MSC lines, are more cost-effective, but they also need immunocompatibility measures. Additionally, the potency of stem cells varies. Two batches of MSCs may have different effects. Standardization of cell characterization is necessary to prevent conflicting trial outcomes due to this diversity. Examples include defining potency assays for MSCs, such as their capacity to block T-cell activation in vitro. Like with medications, these treatments will be thoroughly evaluated by oversight organizations such as the FDA to ensure consistency and safety.

Ethical and Philosophical Concerns

There remain ethical concerns around the use of stem cells, particularly those derived from embryos [13]. Any use of ESCs or fetal tissue, such as fetal NSCs, will be subject to ethical assessment, even though iPSCs circumvent the embryo dilemma. Treatments made from embryonic tissue may not be well-received by certain patients or populations. Additionally, there are ethical issues with using stem cell therapies in psychiatry. Since identity is stored in the brain, treatments that modify the brain may theoretically impact a person's personality or sense of self [13]. Another issue is that the capacity of patient consent in individuals with schizophrenia may be difficult to determine, particularly if they are exhibiting symptoms. It is crucial to guarantee fully informed consent for an experimental treatment in a susceptible group. To protect patient rights and to monitor for exploitation.

Societal and Cost Challenges

If stem cell therapies prove functional, distributing them to a wide range of people who have schizophrenia is a challenge. Schizophrenia affects millions of people globally, many of whom live in areas with limited resources. At least initially, stem cell treatments are likely to be quite expensive and might require specialist services. This calls on the current disparities in health care and accessibility [2]. Schizophrenia patients already deal with substantial expenses due to chronic care. If an expensive treatment can reduce hospitalizations and enhance functional outcomes, its cost may be justifiable in the long run. If treatments using stem cells become widespread, these issues will need to be addressed by insurers and policymakers.

Conclusion and Future Directions

Stem cell therapy is a promising investigational avenue in schizophrenia by modulating neural circuits and supporting regenerative processes, rather than only treating its symptoms. The information that has been accumulated thus far, ranging from bench experiments to early clinical investigations, is encouraging because stem cells can modify detrimental inflammation linked to schizophrenia, induce neuroplastic alterations, support inhibitory circuitry, and stimulate neurogenesis.

In animal models, these therapies result in fewer schizophrenia-like symptoms, particularly in domains of social interaction, cognitive flexibility, and sensory gating, which are underserved by existing treatments. A major initial step toward clinical translation has been taken with the establishment of safety and even the suggestion of cognitive improvements in early human trials. Therefore, stem cell-based therapies present a whole different approach for treating schizophrenia, one that emphasizes brain function restoration and regeneration rather than only neurotransmitter blocking.

Despite the potential, much more research needs to be done before stem cell therapies are implemented to treat schizophrenia. In upcoming years, we are likely to see results indicating where future directions will lead. Research will continue to establish which cell types provide the best clinical outcomes. A mix of cell types may work best, such as when neural progenitors are used in conjunction with MSCs for immunomodulation and circuit repair. More effective treatments may be possible with bioengineered stem cells that have improved characteristics, such as interneuron precursors produced from gene-edited iPSCs. The leading candidates for advanced clinical trials will be identified with the aid of comparative research in animal models.

Comprehensive studies with randomized control must replace circumstantial and open-label studies in this sector. These trials must evaluate effectiveness on significant clinical endpoints in schizophrenia, such as negative symptom scales, cognitive test performance, functional outcomes, and possibly a decrease in hospitalizations or relapse rates. To quantify biological impact objectively, they should also include biomarkers, such as blood indicators of inflammation, EEG markers of circuit function, and MRI evaluations of brain volume or connectivity. These studies will help determine which patients benefit most from stem cell therapy and whether it can live up to its potential.

Stem cell treatments are likely to be utilized alongside regular therapy, rather than as independent treatments. Future studies could examine the most effective ways to combine stem cell therapy with psychotherapy, antipsychotic drugs, or more recent therapies like neuromodulation. To optimize benefits, one interesting approach is to combine stem cell therapies with pro-cognitive or pro-plasticity drugs. Another approach is sequential therapy, which involves employing stem cell therapy to induce brain changes and then solidifying those benefits with focused skill training for the patient. On the other hand, we need to investigate the potential effects of antipsychotic medications on transplanted cells or the other way around. Patient safety will rely on the compatibility of the two.

There are new opportunities to investigate the biology of schizophrenia when treatments enter clinical trials. It may be

possible to identify the diseased processes that were present and modified through studying the changes in the brains of a subset of patients who respond very well to a stem cell treatment. A successful MSC trial, for instance, may highlight the part inflammation plays in that subtype of schizophrenia. However, if some patients do not reply, success predictions can be found by comparing responders and non-responders. Clinical studies can thus contribute to a more complex knowledge of the recovery mechanisms and subtypes of schizophrenia. Essential information could be obtained from advanced imaging and perhaps even post-mortem examinations of any deceased patients.

Future research must also create the logistical and ethical foundations necessary to enable these treatments. This entails educating neurologists and psychiatrists about stem cell therapies, forming interdisciplinary teams of immunologists, cell manufacturing experts, and neurosurgeons, and setting up registries to monitor the long-term results of patients who have received treatment. To regulate expectations and steer clear of expectation traps, public involvement and education will be vital. The future challenges will also include ensuring fair access to care if a therapy proves beneficial; initiatives like lowering production costs and providing treatment assistance for those who cannot pay for them would require attention.

While the path toward stem cell therapy for schizophrenia is risky and challenging, it holds promise for altering our knowledge of and approach to treating this illness. Long regarded as one of the most unresponsive conditions in psychiatry, schizophrenia frequently results in lifelong impairment. The emergence of regeneration techniques marks a new era, offering the possibility that we may one day partially restore or support the impaired neurological system and assist people with schizophrenia in regaining aspects of function and autonomy that are often limited by the illness. The advancements made thus far support further funding for this field of study, even though we must balance optimism with scientific rigor.

References

1. Kim YK, Na KS, Myint AM, et al. Neuroprotection in schizophrenia and its therapeutic implications. Psychiatry Investig. 2017; 14: 383-391.
2. Villanueva R. Stem cell therapy for the treatment of psychiatric disorders: a real hope for the next decades. Front Psychiatry. 2025; 15: 1492415.
3. Tsivion-Visbord H, Perets N, Sofer T, et al. Mesenchymal stem cells derived extracellular vesicles improve behavioral and biochemical deficits in a phencyclidine model of schizophrenia. Transl Psychiatry. 2020; 10: 305.
4. Howes OD, Cummings C, Chapman GE, et al. Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes. Neuropsychopharmacology. 2023; 48: 151-167.
5. Zhong XL, Huang Y, Du Y, et al. Unlocking the therapeutic potential of exosomes derived from nasal olfactory mucosal mesenchymal stem cells: restoring synaptic plasticity, neurogenesis, and neuroinflammation in schizophrenia. Schizophr Bull. 2024; 50: 600-614.
6. Donegan JJ, Tyson JA, Branch SY, et al. Stem cell-derived interneuron transplants as a treatment for schizophrenia: preclinical validation in a rodent model. Mol Psychiatry. 2017; 22: 1352-1359.
7. Gobshtis N, Tfilin M, Fraifeld VE, et al. Transplantation of mesenchymal stem cells causes long-term alleviation of schizophrenia-like behaviour coupled with increased neurogenesis. Mol Psychiatry. 2021; 26: 4448-4463.
8. Coquery N, Blesch A, Stroh A, et al. Intrahippocampal transplantation of mesenchymal stromal cells promotes neuroplasticity. Cytotherapy. 2012; 14: 1041-1053.
9. Panda B, Sharma Y, Gupta S, et al. Mesenchymal stem cell-derived exosomes as an emerging paradigm for regenerative therapy and nanomedicine: A comprehensive review. Life (Basel). 2021; 11: 784.
10. De Gioia R, Biella F, Citterio G, et al. Neural stem cell transplantation for neurodegenerative diseases. Int J Mol Sci. 2020; 21: 3103.
11. You MJ, Bang M, Park HS, et al. Human umbilical cord-derived mesenchymal stem cells alleviate schizophrenia-relevant behaviors in amphetamine-sensitized mice by inhibiting neuroinflammation. Transl Psychiatry. 2020; 10: 123.
12. Cui X, Chen T, Xue Y, et al. Human umbilical cord blood mesenchymal stem cells mediate microglia activation and improve anxiety-like behavior in MIA-induced offspring of schizophrenic rats. Prog Neuropsychopharmacol Biol Psychiatry. 2024; 133: 111010.
13. Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev. 2009; 30: 204-213.
14. Bedel A, Beliveau F, Lamrissi-Garcia I, et al. Preventing pluripotent cell teratoma in regenerative medicine applied to hematology disorders. Stem Cells Transl Med. 2017; 6: 382-393.
15. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 663-676.
16. Perrottelli A, Marzocchi FF, Caporusso E, et al. Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models. J Psychiatry Neurosci. 2024; 49: E109-E125.
17. Bellon A. Comparing stem cells, transdifferentiation and brain organoids as tools for psychiatric research. Transl Psychiatry. 2024; 14: 127.
18. Mei R, Wan Z, Yang C, et al. Advances and clinical challenges of mesenchymal stem cell therapy. Front Immunol. 2024; 15: 1421854.
19. Liesveld JL, Sharma N, Aljitawi OS, et al. Stem cell homing: From physiology to therapeutics. Stem Cells. 2020; 38: 1241-1253.

20. Ternovoy S, Ustyuzhanin D, Morozova Y, et al. Functional MRI evinces the safety and efficacy of umbilical cord blood cell therapy in patients with schizophrenia (pilot study). Schizophr Res. 2020; 224: 175-177.

21. Schoenfeld TJ, Cameron HA. Adult neurogenesis and mental illness. Neuropsychopharmacology. 2015; 40: 113-128.

22. Reif A, Fritzen S, Finger M, et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry. 2006; 11: 514-522.

23. Chang JW, Na HK, Chang KW, et al. Phase 1/2a clinical trial of hESC-derived dopamine progenitors in Parkinson's disease. Cell. 2025; 188: 7036-7048.